2004
January
February
March
April
May
June
July
August
September
October
November
December
HIV/AIDS-Associated Lipodystrophy: Interleukin-18 linked to HIV-associated lipodystrophy AIDSWEEKLY Plus; Monday, December 27, 2004
Staff Medical Writers Interleukin-18 is linked to HIV-associated lipodystrophy. According to published research from Denmark, "IL-18 is an inducer of apoptosis/tissue injury. IL-18 messenger RNA expression was examined in adipose tissue (AT) obtained from HIV patients with lipodystrophy, without lipodystrophy and healthy controls." HIV/AIDS Therapy: Risk of virologic failure with LPV/r increased in children pretreated with PIs AIDSWEEKLY Plus; Monday, December 27, 2004
Staff Medical Writers The risk of virologic failure with lopinavir/ritonavir is increased in children pretreated with protease inhibitors. Antiretroviral Monitoring: Therapeutic drug monitoring simplified for twice-daily lopinavir/ritonavir AIDSWEEKLY Plus; Monday, December 27, 2004
Staff Medical Writers Therapeutic drug monitoring is simplified for twice-daily lopinavir/ritonavir. HIV/AIDS Research: Viremic HIV-1 infection associated with increased overall NK cell activity AIDSWEEKLY Plus; Monday, December 20, 2004
Staff Medical Writers Viremic HIV-1 infection is associated with increased overall natural killer (NK) cell activity. HIV/AIDS Disease Progression: Selenium status associated with increased HIV disease progression in pregnancy AIDSWEEKLY Plus; Monday, December 20, 2004
Staff Medical Writers Selenium status is associated with increased HIV disease progression in pregnant women. HIV/AIDS & Tuberculosis: TB enhances efficient HIV transmission in lower respiratory tract mucosa AIDSWEEKLY Plus; Monday, December 20, 2004
Staff Medical Writers Tuberculosis enhances efficient HIV transmission in the lower respiratory tract mucosa. HIV/AIDS Research: RTF prevents bystander T-cell death associated with HIV infection AIDSWEEKLY Plus; Monday, December 13, 2004
Staff Medical Writers Regeneration and tolerance factor prevents bystander T-cell death associated with HIV infection. HIV/AIDS Research: Galantamine and nicotine inhibit HIV-1 gp120-induced microglial activation AIDSWEEKLY Plus; Monday, December 13, 2004
Staff Medical Writers Galantamine and nicotine synergistically inhibit HIV-1 gp120-induced microglial activation. HIV/AIDS Healthcare: HIV-1 genotype/virtual phenotype correlate for predicting PI/NNRTI resistance AIDSWEEKLY Plus; Monday, December 13, 2004
Staff Medical Writers HIV-1 genotype and virtual phenotype correlates for predicting protease inhibitor and resistance. HIV/AIDS Research: Prostratin inhibits infection/reactivates latent HIV in PBLs/lymphoid tissue AIDSWEEKLY Plus; Monday, December 6, 2004
Staff Medical Writers Prostratin inhibits infection and reactivates latent HIV in peripheral blood lymphocytes and lymphoid tissue. HIV/AIDS Research: Novel method targeting HIV-1-Ag-SCs identifies latently HIV-1-infected CD4 cells AIDSWEEKLY Plus; Monday, December 6, 2004
Staff Medical Writers A novel method targeting HIV-1-antigen-secreting cells identifies latently HIV-1-infected CD4 cells. HIV/AIDS Infection: HIV-1 DNA burden stable in monocytes and CD4 cells after ART resumption AIDSWEEKLY Plus; Monday, December 6, 2004
Staff Medical Writers HIV-1 DNA burden is stable in monocytes and CD4 cells after the resumption of antiretroviral therapy.
HIV/AIDS Therapy: Protease inhibitor fosamprenavir potent against advanced HIV disease AIDSWEEKLY Plus; Monday, November 29, 2004
Staff Medical Writers The protease inhibitor fosamprenavir is potent against advanced HIV disease. HIV/AIDS Research: High-throughput assay identifies CCR5/CD4-mediated HIV virus entry inhibitors AIDSWEEKLY Plus; Monday, November 29, 2004
Staff Medical Writers A novel, high-throughput cell fusion assay identifies CCR5/CD4-mediated HIV virus entry inhibitors. HIV/AIDS Diagnostics: Rapid field test sensitive and specific for detecting/differentiating HIV types AIDSWEEKLY Plus; Monday, November 29, 2004
Staff Medical Writers A rapid field test is sensitive and specific for the detection and differentiation of HIV types 1 and 2. HIV/AIDS Risk: Adolescent woman may be more susceptible to HIV infection than men in Cameroon AIDSWEEKLY Plus; Monday, November 22, 2004
Staff Medical Writers "Adolescents are the focus of many interventions that aim to prevent HIV transmission. In order for these interventions to be effective, it is essential to understand adolescents' sexual behavior. HIV/AIDS Perinatal Transmission: Nevirapine does not prevent perinatal HIV-1 transmission in the field AIDSWEEKLY Plus; Monday, November 22, 2004
Staff Medical Writers Nevirapine does not prevent perinatal HIV-1 transmission in the field. Antiretroviral Therapy: Antiretroviral CSF penetration improves cognitive disorders in HIV infection AIDSWEEKLY Plus; Monday, November 22, 2004
Staff Medical Writers Antiretroviral therapy penetration of the cerebrospinal fluid improves cognitive disorders in HIV infection. HIV/AIDS Vertical Transmission: HIV subtype C preferentially transmitted in utero over subtypes A or D AIDSWEEKLY Plus; Monday, November 15, 2004
Staff Medical Writers HIV subtype C is preferentially transmitted in utero over subtypes A or D. HIV/AIDS Risk Factor: HSV-2 is key risk factor in promoting HIV transmission AIDSWEEKLY Plus; Monday, November 15, 2004
Staff Medical Writers HSV-2 is a key risk factor in promoting HIV transmission. HIV/AIDS Research: Macaques infected with SIV chimera containing HIV-1 RT useful for NNRTI studies AIDSWEEKLY Plus; Monday, November 15, 2004
Staff Medical Writers Macaques infected with an SIV chimera containing HIV-1 reverse transcriptase is useful for studying nonnucleoside RT inhibitors. HIV/AIDS Therapy: HAART interruptions have a negative effect on CD4 cell increase AIDSWEEKLY Plus; Monday, November 8, 2004
Staff Medical Writers Highly active antiretroviral treatment interruptions have a negative effect on CD4 cell increase in HIV infection. HIV/AIDS Drug Resistance: Primary drug resistance persists in recently HIV-1 infected adults AIDSWEEKLY Plus; Monday, November 8, 2004
Staff Medical Writers Primary drug resistance persists in recently HIV-1 infected adults. HIV/AIDS Diagnostics: Cobas Amplicor HIV Monitor 1.5 test modified to measure proviral DNA in PBMCs AIDSWEEKLY Plus; Monday, November 8, 2004
Staff Medical Writers The Cobas Amplicor HIV Monitor 1.5 test was modified to measure proviral DNA in peripheral blood mononuclear cells. HIV/AIDS Research: Dying cells drive the capacity of HIV-1 to kill noncycling primary CD4+ cells AIDSWEEKLY Plus; Monday, November 1, 2004
Staff Medical Writers Dying, neighboring cells drive the capacity of HIV-1 to kill noncycling primary CD4+ cells. HIV/AIDS Epidemiology: HIV-1 non-B subtypes from heterosexual transmission predominate in Scotland AIDSWEEKLY Plus; Monday, November 1, 2004
Staff Medical Writers HIV-1 non-B subtypes acquired from heterosexual transmissions predominate in Scotland. Disease Transmission: Study identifies target for preventing sexual transmission of HIV AIDSWEEKLY Plus; Monday, November 1, 2004
Staff Medical Writers Researchers have shown that it may be possible to block male-to-female HIV transmission in heterosexual intercourse and have identified the target for blocking that transmission.
HIV/AIDS Therapy: Novel technique monitors safety/efficacy of HIV therapy AIDSWEEKLY Plus; Monday, October 11, 2004
Staff Medical Writers Novel technique monitors the safety and efficacy of HIV therapy. HIV/AIDS Therapy: HIV salvage therapy safe and effective in patients with >200 CD4+ cell counts AIDSWEEKLY Plus; Monday, October 11, 2004
Staff Medical Writers HIV salvage therapy is safe and effective in patients with >200 CD4+ cell counts. HIV/AIDS Epidemiology: HIV-1 subtypes unchanged among heterosexuals in England and Wales from 1997-2000 AIDSWEEKLY Plus; Monday, October 4, 2004
Staff Medical Writers HIV-1 subtypes remain unchanged among heterosexuals in England and Wales between 1997 and 2000.
HIV/AIDS Drug Resistance: Antiretroviral resistance mutations detected by high-density DNA probe arrays AIDSWEEKLY Plus; Monday, September 27, 2004
Staff Medical Writers Antiretroviral resistance mutations are detected by high-density DNA probe arrays. HIV/AIDS Research: Replication-competent HIV-2 found in patients with undetectable viremia AIDSWEEKLY Plus; Monday, September 20, 2004
Staff Medical Writers Replication-competent HIV-2 is found in patients with undetectable viremia. HIV/AIDS Research: Progenitor cells may be a reservoir for HIV-1 in the brains of infected patients AIDSWEEKLY Plus; Monday, September 20, 2004
Staff Medical Writers Progenitor cells may be a reservoir for HIV-1 in the brains of infected patients. HIV/AIDS Gene Therapy: Novel target site for gene therapy may control/manage HIV-1 infection AIDSWEEKLY Plus; Monday, September 20, 2004
Staff Medical Writers A novel target site for gene therapy may control/manage HIV-1 infection. HIV/AIDS Pathogenesis: HIV-1 evolution/immunological responses similar at 10 years despite therapies AIDSWEEKLY Plus; Monday, September 13, 2004
Staff Medical Writers HIV-1 evolution and immunological responses are similar after 10 years, despite various therapeutic strategies. HIV/AIDS Exposure: New guidelines maximize effects of occupational HIV post-exposure prophylaxis AIDSWEEKLY Plus; Monday, September 13, 2004
Staff Medical Writers New guidelines maximize the effects of occupational HIV post-exposure prophylaxis. Antiretroviral Therapy: Specific genotype correlates with high plasma efavirenz levels in HIV patients AIDSWEEKLY Plus; Monday, September 13, 2004
Staff Medical Writers HIV/AIDS Diagnostics: Immuno-PCR for HIV-1 p24 antigen lowers HIV-1 viral load detection limits AIDSWEEKLY Plus; Monday, September 6, 2004
Staff Medical Writers According to recent research published in the American Journal of Clinical Pathology , "Presently, the assay that attains maximal sensitivity and dynamic range of HIV-1 viral copy number (50 copies per milliliter) is nucleic acid amplification of HIV RNA in plasma. HIV/AIDS Epidemic: Free antiretroviral therapy distributed to six most needy states in India AIDSWEEKLY Plus; Monday, September 6, 2004
Staff Medical Writers According to recent research from the United States, "India has a population of more than 1 billion people. Although only about 0.7% of its population is infected with HIV, it has more cases than any other country in the world, with more than 4.5 million HIV-seropositive patients." AIDS/HIV Therapy: Systematic HAART for HIV patients with >500 T cell counts not supported by data AIDSWEEKLY Plus; Monday, September 6, 2004
Staff Medical Writers The data does not support systematic highly active antiretroviral therapy for HIV patients with >500 T cell counts.
HIV/AIDS Research: Reduced glutathione and cysteine levels associated with HIV disease progression AIDSWEEKLY Plus; Monday, August 30, 2004
Staff Medical Writers Reduced glutathione and cysteine levels are associated with HIV disease progression. HIV/AIDS Research: Mast cells may serve as a viral reservoir for HIV-1 AIDSWEEKLY Plus; Monday, August 30, 2004
Staff Medical Writers "Evidence that human progenitor mast cells are susceptible to infection with CCR5-tropic strains of HIV-1 and that circulating HIV-1-infected FcERIalpha+ cells with a similar progenitor phenotype have been isolated from AIDS patients has led to speculation that mast cells may serve as a potential reservoir for infectious HIV-1, wrote scientists in the United States. HIV/AIDS Gene Therapy: Lentivirus-based antisense vector inhibits HIV replication AIDSWEEKLY Plus; Monday, August 30, 2004
Staff Medical Writers "We present preclinical studies that demonstrate in vitro the feasibility and efficacy of lentivirus-based vector antisense gene therapy for control of HIV replication in primary T lymphocytes isolated from HIV-infected patients discordant for clinical status. HIV/AIDS Research: CD4 expression allows infection of CD8 cells by HIV AIDSWEEKLY Plus; Monday, August 23, 2004
Staff Medical Writers CD4 expression allows for infection of CD8 cells by HIV. HIV/AIDS Epidemiology: Global burden of HIV/AIDS best estimated using plausible ranges AIDSWEEKLY Plus; Monday, August 23, 2004
Staff Medical Writers The global burden of HIV/AIDS is best estimated using plausible ranges. Antiretroviral Therapy: Ritonavir/ritonavir-boosted saquinavir does not effect saquinavir action AIDSWEEKLY Plus; Monday, August 23, 2004
Staff Medical Writers Ritonavir or ritonavir-boosted saquinavir for treatment of HIV infection does not effect saquinavir pharmacokinetics. HIV/AIDS Screening: Use of two HIV antibody screening tests increase false-positive rate AIDSWEEKLY Plus; Monday, August 16, 2004
Staff Medical Writers The use of two HIV antibody screening tests increases the rate of false-positive results. Antiretroviral Therapy: Addition of tenofovir decreases AUC for atazanavir in HIV-treated patients AIDSWEEKLY Plus; Monday, August 16, 2004
Staff Medical Writers The addition of tenofovir decreases the area-under-the-curve for atazanavir in HIV-treated patients. Antiretroviral Drug Resistance: Long-term suppression of HIV RNA with HAART occur despite virus evolution AIDSWEEKLY Plus; Monday, August 16, 2004
Staff Medical Writers The long-term suppression of HIV RNA with highly active antiretroviral therapy occurred despite virus evolution. HIV/AIDS Research: HIV-1 RNA level in cervical secretions influenced by menstrual cycle AIDSWEEKLY Plus; Monday, August 9, 2004
Staff Medical Writers HIV-1 RNA level in cervical secretions is influenced by the menstrual cycle. HIV/AIDS Blood Safety: Nucleic acid testing for HIV-1 and HIV-2 increases safety of donated blood AIDSWEEKLY Plus; Monday, August 9, 2004
Staff Medical Writers Nucleic acid testing for HIV-1 and HIV-2 increases the safety of donated blood. HIV/AIDS: Increased cancers among HIV-infected prisoners linked to high-risk behavior AIDSWEEKLY Plus; Monday, August 9, 2004
Staff Medical Writers According to a study from the U.S., "HIV-associated immunosuppression has been linked to an increased risk of a number of cancers, including Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and invasive cervical cancer. HIV/AIDS-Related Disease: HAART increases survival of patients with HIV-associated Hodgkin disease AIDSWEEKLY Plus; Monday, August 2, 2004
Staff Medical Writers Highly active antiretroviral therapy increases the survival of patients with HIV-associated Hodgkin disease. HIV/AIDS Therapy: Subcutaneous IL-2 therapy maintains CD4 cell increases in HIV-1 infection AIDSWEEKLY Plus; Monday, August 2, 2004
Staff Medical Writers Subcutaneous IL-2 therapy maintains CD4 cell increases in HIV-1 infection. Antiretroviral Therapy: Styrylquinolines do not interfere with HIV entry but act before integration AIDSWEEKLY Plus; Monday, August 2, 2004
Staff Medical Writers SQLs do not interfere with HIV entry but act before integration.
AIDS Therapy: Data on Lexiva/Ritonavir vs. Nelfinavir study published AIDSWEEKLY Plus; Monday, July 26, 2004
Staff Medical Writers The protease inhibitor (PI) Lexiva (fosamprenavir calcium) dosed with ritonavir (Lexiva/r) once-daily (QD) as part of a first-line ART regimen provided antiviral suppression that was comparable in this single study to the PI nelfinavir (NFV) dosed twice-daily (BID), according to 48-week data from the SOLO trial published in the journal AIDS HIV/AIDS Research: CpG oligodeoxynucleotides activate HIV replication in latently infected T cells AIDSWEEKLY Plus; Monday, July 26, 2004
Staff Medical Writers CpG oligodeoxynucleotides activate HIV replication in latently infected T cells. HIV/AIDS Diagnostics: ViroSeq HIV-1 Genotyping System has decreased performance with non-B subtypes AIDSWEEKLY Plus; Monday, July 26, 2004
Staff Medical Writers The ViroSeq HIV-1 Genotyping System has decreased performance with non-B subtypes. HIV/AIDS Therapy: ART efficacy after protease inhibitor failure better in NNRTI-naive patients AIDSWEEKLY Plus; Monday, July 19, 2004
Staff Medical Writers Antiretroviral therapy efficacy after protease inhibitor failure is better in nonnucleoside reverse-transcriptase inhibitor patients. HIV/AIDS Research: Potential protective effect of HLA DQB1*06 alleles on course of HIV disease AIDSWEEKLY Plus; Monday, July 19, 2004
Staff Medical Writers There is a potential protective effect of HLA DQB1*06 alleles on the course of HIV disease. HIV/AIDS Research: HIV-1 immune response differs in exposed seronegative and seropositive partners AIDSWEEKLY Plus; Monday, July 19, 2004
Staff Medical Writers HIV-1 immune response differs in exposed seronegative and their seropositive partners. HIV/AIDS Research: HIV viral load of subtype C underestimated in assays optimized for subtype B AIDSWEEKLY Plus; Monday, July 12, 2004
Staff Medical Writers HIV viral loads from patients with subtype C are underestimated in assays that are optimized for subtype B. Genomics: Genomic selection strategy likely to define targets relevant for HIV-1 therapy AIDSWEEKLY Plus; Monday, July 12, 2004
Staff Medical Writers A developed genomic selection strategy is likely to define targets relevant for HIV-1 therapy. HIV/AIDS Dementia: International study will evaluate neurological disease in HIV/AIDS patients AIDSWEEKLY Plus; Monday, July 5, 2004
Staff Medical Writers Researchers at the University of North Carolina (UNC) at Chapel Hill are preparing to launch an international clinical trial studying neurological disease in people with HIV and AIDS that is believed to be one of the largest neurological studies ever undertaken in the developing world. Diagnostics: New strategies detect HIV earlier and more effectively than ever AIDSWEEKLY Plus; Monday, July 5, 2004
Staff Medical Writers Researchers at the Institute of Human Virology (IHV) have developed an ultra-sensitive testing technique that has shown the ability to detect HIV infection earlier than all current methods. This new diagnostic approach combines two existing models and is 25 times more sensitive than the best technology currently available.
HIV/AIDS Progression: Timed ablation of regulatory CD4+ T cells prevents AIDS progression AIDSWEEKLY Plus; Monday, June 21, 2004
Staff Medical Writers Timed ablation of regulatory CD4+ T cells prevents AIDS progression in mice. HIV/AIDS: Intracellularly expressed HIV-1 Tat protein inhibits neural cell proliferation AIDSWEEKLY Plus; Monday, June 21, 2004
Staff Medical Writers Intracellularly expressed HIV-1 Tat protein inhibits neural cell proliferation. HIV/AIDS: Ezrin/CD95 linkage key role regulating susceptibility to CD95-mediated apoptosis AIDSWEEKLY Plus; Monday, June 21, 2004
Staff Medical Writers Ezrin/CD95 linkage has a key role regulating susceptibility to CD95-mediated apoptosis. Epidemiology: HIV/AIDS disproportionately affects African American women AIDSWEEKLY Plus; Monday, June 14, 2004
Staff Medical Writers The Black Women's Health Imperative used HIV Vaccine Awareness Day, May 18, 2004, as an opportunity to educate African American women about the impact of HIV/AIDS on them and to help them learn more about HIV vaccine research. Antiretroviral Therapy: Efavirenz induces strong inhibition of SREBP-1c-dependent lipogenic pathway AIDSWEEKLY Plus; Monday, June 14, 2004
Staff Medical Writers Efavirenz induces a strong inhibition of the SREBP-1c-dependent lipogenic pathway. AIDS Therapy: Data on first Fuzeon international consensus guidelines published AIDSWEEKLY Plus; Monday, June 14, 2004
Staff Medical Writers International consensus guidelines for Fuzeon (enfuvirtide), the first and only fusion inhibitor available for the treatment of HIV, were published in AIDS , the official journal of the International AIDS Society. AIDS: Scientists discover how AIDS opens cell doors AIDSWEEKLY Plus; Monday, June 7, 2004
Staff Medical Writers Researchers at the Salk Institute have discovered a way to view viruses like HIV upon cell entry. HIV/HCV Treatment: HCV therapy with IFN/RBV relatively safe in patients coinfected with HIV and HCV AIDSWEEKLY Plus; Monday, June 7, 2004
Staff Medical Writers HCV therapy with interferon plus ribovarin is relatively safe in patients coinfected with HIV and HCV. HIV/AIDS Virology: HIV-1 viral load and infectivity reduced in presence of cellular prion protein AIDSWEEKLY Plus; Monday, June 7, 2004
Staff Medical Writers HIV-1 viral load and infectivity is reduced in the presence of cellular prion proteins.
AIDS/HIV Genomics and Genetics: Wild-type CCR5 confers HIV-1 cross-clade resistance AIDSWEEKLY Plus; Monday, May 31, 2004
Staff Medical Writers Scientists describe risk associated HIV-1 cross-clade resistance of whole peripheral blood mononuclear cells from exposed uninfected individuals with wild-type CCR5. HIV/AIDS Treatment: Deep salvage with amprenavir and lopinavir/ritonavir partially effective AIDSWEEKLY Plus; Monday, May 31, 2004
Staff Medical Writers Deep salvage with amprenavir and lopinavir/ritonavir is partially effective. HIV/AIDS: HIV-1 viral load increase confers virus escape risk via recombination diversity AIDSWEEKLY Plus; Monday, May 31, 2004
Staff Medical Writers HIV-1 viral load increase confers a risk of virus escape via recombination diversity. HIV/AIDS: Nonpeptidic protease inhibitor tipranavir effective against HIV-1 in vivo AIDSWEEKLY Plus; Monday, May 24, 2004
Staff Medical Writers The nonpeptidic protease inhibitor tipranavir is safe and effective against HIV-1 in vivo . HIV/AIDS: Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART AIDSWEEKLY Plus; Monday, May 24, 2004
Staff Medical Writers Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART in HIV-1-infected patients. HIV/AIDS: Genome distribution of HIV-1 dependent on viremia level AIDSWEEKLY Plus; Monday, May 24, 2004
Staff Medical Writers Genome distribution of HIV-1 is dependent on the level of viremia. HIV/AIDS Epidemiology: HIV infection progresses to AIDS faster in developing countries AIDSWEEKLY Plus; Monday, May 17, 2004
Staff Medical Writers The progression from HIV infection to AIDS and death from AIDS is more rapid in people living in developing countries than those living in the United States and Europe, according to researchers from the Johns Hopkins Bloomberg School of Public Health, the Armed Forces Research Institute of Medical Sciences and Chiang Mai University in Thailand. Endocrinology: Testosterone replacement improves muscle strength, function in HIV+ women AIDSWEEKLY Plus; Monday, May 17, 2004
Staff Medical Writers Researchers at Massachusetts General Hospital (MGH) have found that restoring normal levels of testosterone can improve muscle strength and function in HIV infected women with low levels of the male hormone. AIDS Therapy: FDA-approved study launched to treat AIDS patients in virologic failure AIDSWEEKLY Plus; Monday, May 17, 2004
Staff Medical Writers Advanced Biotherapy, Inc., (ADVB) announced the launch of a phase I U.S. Food & Drug Administration (FDA)-approved clinical trial to initially treat antiretroviral drug-resistant AIDS patients with an inhibitor to Tumor Necrosis Factor-α (TNF-α). Sexually Transmitted Disease: Protective effect of circumcision against HIV has biological explanation AIDSWEEKLY Plus; Monday, May 10, 2004
Staff Medical Writers Biological factors underlie the protective effect of circumcision against HIV infection. HIV/HBV Coinfection: Acute HIV infection linked to stable or reduced HBV loads AIDSWEEKLY Plus; Monday, May 10, 2004
Staff Medical Writers Surprisingly, acute HIV infection appears to reduce HBV loads in hepatitis B patients. HIV/AIDS Pediatric: Naïve, infection-resistant lymphocytes dominate immune recovery in children AIDSWEEKLY Plus; Monday, May 10, 2004
Staff Medical Writers Immune recovery in pediatric HIV patients primarily involves naïve, infection-resistant lymphocytes. HIV/AIDS Therapy: In utero AZT exposure has little or no impact on neurodevelopment AIDSWEEKLY Plus; Monday, May 3, 2004
Staff Medical Writers Exposure to the antiretroviral agent azidothymidine (AZT) in utero does not have a significant impact on neurodevelopment. HIV/AIDS Epidemiology: Muslim areas in Africa have lower rates of HIV infection AIDSWEEKLY Plus; Monday, May 3, 2004
Staff Medical Writers Islam may be linked to reduced rates of HIV infection in Africa. HIV/AIDS Enzymology: E152 amino acid region of HIV integrase characterized AIDSWEEKLY Plus; Monday, May 3, 2004
Staff Medical Writers The region of HIV integrase carrying the E152 amino acid has been characterized.
HIV/AIDS Therapy: Anti-NeoR6 resistance mutations suggest anti-HIV mechanisms AIDSWEEKLY Plus; Monday, April 26, 2004
Staff Medical Writers The identification of HIV mutations conferring resistance to NeoR6 has provided clues to its antiretroviral mechanisms. Drug Development: Plant-derived liminoids exhibit potent antiretroviral activity AIDSWEEKLY Plus; Monday, April 26, 2004
Staff Medical Writers The potent antiretroviral effects of a pair of liminoids have been characterized. Drug Development: Lavendamycin analogues show promise as HIV reverse transcriptase inhibitors AIDSWEEKLY Plus; Monday, April 26, 2004
Staff Medical Writers A series of lavendamycin analogues show promise as HIV reverse transcriptase inhibitors. HIV/AIDS Immune Control: Scavenger function of CCR5Δ32 protein involved in protection from HIV AIDSWEEKLY Plus; Monday, April 19, 2004
Staff Medical Writers Coreceptor scavenging helps protect against HIV infection in individuals with the CCR5Δ32 mutation. Drug Development: Anti-HIV activity of linear peptide gp120 inhibitors characterized AIDSWEEKLY Plus; Monday, April 19, 2004
Staff Medical Writers The anti-HIV activity of linear peptide gp120 inhibitors has been characterized. Drug Development: Lipophilic substitutions improve benzylpyrazole CCR5 antagonists AIDSWEEKLY Plus; Monday, April 19, 2004
Staff Medical Writers Lipophilic substitutions improve the overall efficacy of anti-HIV benzylpyrazole-based CCR5 antagonists. Atherosclerosis: Heart disease more common, progresses quicker in HIV patients AIDSWEEKLY Plus; Monday, April 12, 2004
Staff Medical Writers Now that treatments have been successful at helping HIV patients live longer, these patients are facing a new health challenge - high rates of rapidly progressive atherosclerosis, researchers report. HIV/AIDS Dyslipidemia: Bone mineral loss frequent in female patients during HAART AIDSWEEKLY Plus; Monday, April 12, 2004
Staff Medical Writers The metabolic disruption associated with antiretroviral therapy often manifests as bone mineral density (BMD) loss in female HIV patients. HIV/AIDS Therapy: HIV-infected cells have heightened vulnerability to electrical damage AIDSWEEKLY Plus; Monday, April 12, 2004
Staff Medical Writers HIV-infected cells are more susceptible to electrical damage than uninfected cells, a feature that could be exploited for novel anti-HIV therapies. HIV/AIDS Women's Health: Vitamin A supplements may increase risk of vertical HIV transmission AIDSWEEKLY Plus; Monday, April 5, 2004
Staff Medical Writers Vitamin A supplements may increase the risk of vertical HIV transmission. HIV/AIDS Therapy: Routine resistance testing can improve ART outcome in experienced patients AIDSWEEKLY Plus; Monday, April 5, 2004
Staff Medical Writers Routine resistance testing can improve the outcome of ART in heavily-treated HIV patients. Drug Development: Cell-penetrating, Rev-binding peptides can protect against HIV AIDSWEEKLY Plus; Monday, April 5, 2004
Staff Medical Writers A novel class of cell-penetrating, Rev-binding peptides may protect against HIV infection.
HIV/AIDS Therapy: Protease inhibitors can induce lactic acidosis AIDSWEEKLY Plus; March 29, 2004
Staff Medical Writers HIV protease inhibitors (PIs) can induce lactic acidosis. This condition is "a rare but potentially life-threatening and poorly understood sequelae among HIV-infected patients on highly active antiretroviral therapy (HAART)," scientists in Hawaii explained. "Mitochondrial DNA depletion and inhibition of respiratory complexes have been hypothesized to be involved in HAART-associated lactic acidosis." HIV/AIDS Proteomics: Tat from HIV subtype C has impaired chemotactic ability AIDSWEEKLY Plus; March 29, 2004
Staff Medical Writers The Tat protein from HIV subtype C has impaired chemotactic ability. Drug Development: Novel arylsulfonamides active against drug-resistant HIV AIDSWEEKLY Plus; March 29, 2004
Staff Medical Writers A group of arylsulfonamides have potent activity against drug-resistant strains of HIV. Drug Development: Benzothiepine and benzazepine derivatives show promise as oral CCR5 blockers AIDSWEEKLY Plus; March 22, 2004
Staff Medical Writers Novel benzothiepine and benzazepine derivatives show promise as orally active antagonists of the HIV coreceptor CCR5. Drug Development: PRO 542 shows promise as HIV salvage therapy AIDSWEEKLY Plus; March 22, 2004
Staff Medical Writers PRO 542 shows great promise as a salvage therapy for HIV patients. Drug Development: PBD hybrids disrupt HIV RNA activity AIDSWEEKLY Plus; March 22, 2004
Staff Medical Writers A series of novel PBD hybrids disrupt HIV transcription and RNA activity. AIDS Therapy: Early trial results move investigational CCR5 antagonist to next phase AIDSWEEKLY Plus; March 15, 2004
Staff Medical Writers Results from an early phase clinical trial evaluating a new class of AIDS therapy under development by GlaxoSmithKline (GSK) in healthy volunteers were presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI). HIV/AIDS Immunity: T-cell Fas expression may predict virological outcome AIDSWEEKLY Plus; March 15, 2004
Staff Medical Writers T-cell Fas expression may predict viral control in patients undergoing HIV treatment. Drug Development: Sulfonated anionic porphyrins can induce HIV photo-damage AIDSWEEKLY Plus; March 15, 2004
Staff Medical Writers Sulfonated anionic porphyrins can be used to induce photo-damage in key areas of the HIV coat protein gp120. HIV/AIDS Woman's Health: GBV-C infection has protective effect in HIV+ mothers AIDSWEEKLY Plus; March 8, 2004
Staff Medical Writers GB virus type C (GBV-C) infection has a protective effect in HIV-positive mothers. HIV/AIDS Pathogenesis: Conformation of HIV gp41 during cell entry determined AIDSWEEKLY Plus; March 8, 2004
Staff Medical Writers The conformation of HIV gp41 during cell entry has been determined, providing information that may facilitate the design of novel antiretroviral agents. Drug Development: Cyclohexane derivatives strongly inhibit HIV integrase activity AIDSWEEKLY Plus; March 8, 2004
Staff Medical Writers A series of novel cyclohexane derivatives strongly inhibit HIV integrase activity. HIV/AIDS: Microbead-conjugated anti-gp41 antibodies can isolate HIV-infected cells AIDSWEEKLY Plus; March 1, 2004
Staff Medical Writers Microbead-conjugated anti-gp41 antibodies can be used to enrich for HIV-infected cells. Pediatric HIV/AIDS: HAART induces abnormal bone metabolism, reduces BMD in children AIDSWEEKLY Plus; March 1, 2004
Staff Medical Writers HAART causes abnormal bone metabolism and reduces BMD in children. HIV/AIDS Gene Therapy: Novel gp41-derived peptides inhibit HIV cell entry AIDSWEEKLY Plus; March 1, 2004
Staff Medical Writers Novel gp42-derived peptides inhibit strongly inhibit HIV-cell membrane fusion.
HIV/AIDS Therapy: Interactions with other PIs linked to tenofovir-induced kidney damage AIDSWEEKLY Plus; Monday, February 23, 2004
Staff Medical Writers The causes of kidney damage in HIV patients treated with tenofovir have been elucidated. HIV/AIDS Coinfection: High rate of multiple viral infections in Argentina IDUs AIDSWEEKLY Plus; Monday, February 23, 2004
Staff Medical Writers Multiple viral infections are common in the IDU population of Argentina. HIV/AIDS DNA Research: BAF is a host component of HIV virions; binds Gag and matrix AIDSWEEKLY Plus; Monday, February 23, 2004
Staff Medical Writers Barrier-to-autointegration factor (BAF) is a crucial host component of HIV virions. HIV/AIDS Therapy: Once-daily lamivudine 300 mg equivalent to 150 mg BID AIDSWEEKLY Plus; Monday, February 16, 2004
Staff Medical Writers Treatment with 300 mg of lamivudine once a day is equivalent to 150-mg doses taken twice per day. HIV/AIDS Therapy: Amprenavir prodrug safe and effective, with reduced pill burden AIDSWEEKLY Plus; Monday, February 16, 2004
Staff Medical Writers A novel form of the antiretroviral agent amprenavir provides safe and effective control of HIV infection with a low pill burden. Drug Development: Fungal metabolite inhibits HIV integrase activity AIDSWEEKLY Plus; Monday, February 16, 2004
Staff Medical Writers A novel fungal metabolite has been found to inhibit HIV integrase activity. HIV/AIDS Coinfection: Liver transplantation feasible in HIV/HCV-coinfected patients AIDSWEEKLY Plus; Monday, February 9, 2004
Staff Medical Writers Liver transplantation can be feasible for patients infected with both HIV and hepatitis C virus (HCV). HIV/AIDS Therapy: STAT1 blockade shows promise for clearance of latent HIV reservoirs AIDSWEEKLY Plus; Monday, February 9, 2004
Staff Medical Writers STAT1 blockade shows promise for the clearance of HIV reservoirs in patients with latent infection. Drug Development: Liminoids strongly inhibit HIV protease activity AIDSWEEKLY Plus; Monday, February 9, 2004
Staff Medical Writers A pair of novel liminoids act as potent HIV protease inhibitors. AIDS Diagnosis: Clinton: Costs of AIDS tests will plummet in Africa, Caribbean AIDSWEEKLY Plus; Monday, February 2, 2004
Staff Medical Writers An agreement with five medical technology companies could help reduce the costs of treating HIV-infected people in Africa and the Caribbean by up to 80%, former President Bill Clinton said in announcing a deal brokered by his foundation. Cell Biology: To avoid detection, HIV disrupts immune cell migration AIDSWEEKLY Plus; Monday, February 2, 2004
Staff Medical Writers The HIV protein Nef sparked intensive research after observations that patients with a rare strain of HIV lacking Nef took a very long time to develop AIDS symptoms. Nef has been linked to molecules involved in cell signaling pathways and may use them for its own ends. But how Nef does this has not been clear. HIV/AIDS Pathogenesis: Human leukocyte elastase can act as HIV coreceptor AIDSWEEKLY Plus; Monday, February 2, 2004
Staff Medical Writers Human leukocyte elastase (HLE) can act as an HIV coreceptor.
HIV/AIDS Therapy: Patterns of NRTI cross-resistance identified AIDSWEEKLY Plus; Monday, January 26, 2004
Staff Medical Writers Patterns of HIV nucleoside reverse-transcriptase inhibitor (NRTI) cross-resistance have been identified. HIV/AIDS Receptor Studies: Structure of gp120-CCR5 complex elucidated AIDSWEEKLY Plus; Monday, January 26, 2004
Staff Medical Writers The structure of HIV gp120 in complex with CCR5 has been elucidated. HIV/AIDS Cancer: Interaction between HIV Tat and pRb2/p130 may contribute to oncogenesis AIDSWEEKLY Plus; Monday, January 26, 2004
Staff Medical Writers Interaction between HIV Tat and pRb2/p130 may contribute to oncogenesis. HIV/AIDS Therapy: Distal mutation cooperation needed for HIV multiprotease inhibitor resistance AIDSWEEKLY Plus; Monday, January 19, 2004
Staff Medical Writers Cooperation between distal mutations in HIV protease are necessary for the development of multidrug resistance. HIV/AIDS RNA Research: Homology requirements for optimal antiretroviral shRNA activity clarified AIDSWEEKLY Plus; Monday, January 19, 2004
Staff Medical Writers The homology requirements for optimal antiretroviral shRNA activity have been clarified. HIV Therapy: Best treatment for new HIV patients to be studied AIDSWEEKLY Plus; Monday, January 19, 2004
Staff Medical Writers Primary and early HIV infection represents a potentially unique opportunity to better understand the pathogenesis of HIV infection, as well as to potentially prevent the establishment of latent infection. HIV/AIDS Coinfection: Hepatitis B treatment for HIV patients reviewed AIDSWEEKLY Plus; Monday, January 12, 2004
Staff Medical Writers Current and future options for hepatitis B treatment in HIV patients have been reviewed. Healthcare Access: WHO: Battle against AIDS will founder without boost to basic healthcare AIDSWEEKLY Plus; Monday, January 12, 2004
Staff Medical Writers Global efforts to battle HIV/AIDS and slash infant mortality rates will founder unless the international community boosts basic medical care in poor countries, the U.N. health agency says. Immunology: Shyness can be deadly AIDSWEEKLY Plus; Monday, January 12, 2004
Staff Medical Writers How you react to stress influences how easily you resist or succumb to disease, including viruses like HIV, discovered University of California Los Angeles (UCLA) AIDS Institute scientists. HIV/AIDS Transmission: HIV-1 viral load influences risk of mother-to-child HIV transmission AIDSWEEKLY Plus; Monday, January 5, 2004
Staff Medical Writers Researchers list risk factors for mother-to-child transmission of HIV-1 in a breast-feeding population in a recent issue of the Journal of Acquired Immune Deficiency Syndromes HIV/AIDS Pathogenesis: HIV-exposed but uninfected IDUs have heightened NK-cell activity AIDSWEEKLY Plus; Monday, January 5, 2004
Staff Medical Writers Injecting drug users who remain HIV-negative after extensive exposure have elevated levels of natural killer (NK)-cell activity. HIV/AIDS Therapy: Small-molecule CCR5 inhibitor effective in macaques AIDSWEEKLY Plus; Monday, January 5, 2004
Staff Medical Writers A small-molecule CCR5 inhibitor significantly reduces viremia in macaques infected with the simian version of HIV.
Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim , iMetrikus, Inc. , the National Library of Medicine , and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
